Equities analysts expect Aileron Therapeutics Inc (NASDAQ:ALRN) to announce earnings per share (EPS) of ($0.24) for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Aileron Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.26) and the highest estimate coming in at ($0.22). Aileron Therapeutics reported earnings of ($0.50) per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 52%. The firm is scheduled to report its next earnings results on Wednesday, November 6th.

On average, analysts expect that Aileron Therapeutics will report full year earnings of ($1.14) per share for the current year, with EPS estimates ranging from ($1.27) to ($1.03). For the next financial year, analysts anticipate that the firm will post earnings of ($0.87) per share, with EPS estimates ranging from ($0.91) to ($0.81). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side analysts that that provide coverage for Aileron Therapeutics.

Aileron Therapeutics (NASDAQ:ALRN) last released its quarterly earnings data on Tuesday, August 6th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.03).

ALRN has been the subject of a number of analyst reports. Zacks Investment Research lowered shares of Aileron Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, August 9th. ValuEngine upgraded shares of Aileron Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. HC Wainwright restated a “buy” rating and issued a $6.00 price objective on shares of Aileron Therapeutics in a research report on Wednesday, August 7th. Finally, William Blair restated an “outperform” rating on shares of Aileron Therapeutics in a research report on Monday, May 6th. One analyst has rated the stock with a sell rating and four have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $4.00.

A number of institutional investors have recently made changes to their positions in the business. Jennison Associates LLC lifted its position in Aileron Therapeutics by 649.6% during the first quarter. Jennison Associates LLC now owns 2,040,255 shares of the company’s stock valued at $3,828,000 after purchasing an additional 1,768,073 shares during the last quarter. Deutsche Bank AG lifted its position in Aileron Therapeutics by 432.9% during the fourth quarter. Deutsche Bank AG now owns 129,170 shares of the company’s stock valued at $108,000 after purchasing an additional 104,932 shares during the last quarter. Finally, BlackRock Inc. lifted its position in Aileron Therapeutics by 179.6% during the second quarter. BlackRock Inc. now owns 49,485 shares of the company’s stock valued at $36,000 after purchasing an additional 31,787 shares during the last quarter. Institutional investors and hedge funds own 29.17% of the company’s stock.

ALRN stock opened at $0.61 on Friday. The company has a 50 day moving average price of $0.60. The company has a debt-to-equity ratio of 0.16, a current ratio of 6.04 and a quick ratio of 6.04. Aileron Therapeutics has a 12 month low of $0.44 and a 12 month high of $4.10.

Aileron Therapeutics Company Profile

Aileron Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of therapeutics in the United States. The company's lead product candidate is ALRN-6924, a stapled peptide, which is in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase IIb trial to treat AML/MDS in combination with cytosine arabinoside.

Read More: Should You Consider an Index Fund?

Get a free copy of the Zacks research report on Aileron Therapeutics (ALRN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aileron Therapeutics (NASDAQ:ALRN)

Receive News & Ratings for Aileron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.